| HOME >> BIOLOGY >> TECHNOLOGY |
Stock based
compensation 539,156 403,550 64,104 4,704,805
Other non-cash
items - - 224,508 1,383,537
Net change in
non-cash working
capital 530,300 811,922 584,766 2,435,221
-------------------------------------------------------------------------
Cash used in
operating
activities (13,569,594) (12,155,372) (11,052,462) (66,551,036)
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Intellectual
property (852,498) (842,610) (1,033,035) (6,351,778)
Capital assets (92,221) (35,837) (61,309) (715,569)
Purchase of
short-term
investments (949,496) (1,035,427) (22,195,253) (49,068,963)
Redemption of
short-term
investments 6,573,000 13,808,000 6,656,746 30,151,746
Investment in
BCY LifeSciences
Inc. - - 7,965 464,602
Investment in
Transition
Therapeutics
Inc. - - - 2,532,343
-------------------------------------------------------------------------
Cash provided by
(used in)
investing
activities 4,678,785 11,894,126 (16,624,886) (22,987,619)
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Proceeds from
exercise of
stock options
and warrants 51,000 241,400 3,384,787 15,259,468
Proceeds from
private
placements - - 15,395,402 38,137,385
Proceeds from
public
offerings 12,063,394
'/>"/>
| SOURCE Oncolytics Biotech Inc. Copyright©2008 PR Newswire. All rights reserved |